These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35965073)

  • 1. Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases.
    Kaneko K; Shikano K; Kawazoe M; Kawai S; Nanki T
    Intern Med; 2022; 61(16):2405-2415. PubMed ID: 35965073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
    Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
    Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
    Suzuki T; Nakamura Y; Kato H
    Nutrients; 2018 Feb; 10(3):. PubMed ID: 29495518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids.
    Tamechika SY; Ohmura SI; Maeda S; Naniwa T
    J Bone Miner Metab; 2023 Mar; 41(2):203-211. PubMed ID: 36512086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of denosumab treatment in chronic liver disease patients with osteoporosis.
    Saeki C; Saito M; Oikawa T; Nakano M; Torisu Y; Saruta M; Tsubota A
    World J Gastroenterol; 2020 Sep; 26(33):4960-4971. PubMed ID: 32952342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis.
    Suzuki T; Nakamura Y; Kato H
    Mod Rheumatol; 2018 Sep; 28(5):885-889. PubMed ID: 29251033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
    Suzuki T; Nakamura Y; Kato H
    Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
    [No Abstract]   [Full Text] [Related]  

  • 13. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
    Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
    Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
    Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
    Voskaridou E; Ntanasis-Stathopoulos I; Papaefstathiou A; Christoulas D; Dimopoulou M; Repa K; Papatheodorou A; Peppa M; Terpos E
    Blood Adv; 2018 Nov; 2(21):2837-2847. PubMed ID: 30381400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
    Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
    Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
    Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
    BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
    Kobayashi M; Sawada K; Yoshimura A; Yamamoto M; Shimizu A; Shimura K; Komura N; Miyamoto M; Ishida K; Kimura T
    BMC Womens Health; 2020 Mar; 20(1):48. PubMed ID: 32138724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients.
    Hori M; Yasuda K; Takahashi H; Kondo C; Shirasawa Y; Ishimaru Y; Sekiya Y; Morozumi K; Maruyama S
    Sci Rep; 2022 May; 12(1):7781. PubMed ID: 35546172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.